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OsteoprotegerinAbstract Outcome objectives: To recognize the differential expression of OPG in the otic capsule
of adult male mice compared to other selected skeletal bones both in the nearby location as the tem-
poral bone and in distant bones as the tibia.
Methods: The present experimental study was conducted in 2011 on 20 normal adult male albino
mice with an average weight of 50–60 g. Animal housing at the Physiology department (Alexandria
Faculty of Medicine) followed the rules of research ethics for experimental animals approved by the
Faculty of Medicine, University of Alexandria, Egypt. The following bone specimens were har-
vested from normal adult male albino mice by microdissection: (1) temporal bone, (2) otic capsule
bone surrounding the cochlea, and (3) tibia and stained immunohistochemically for anti-OPG
monoclonal antibody. Positive staining was graded and analyzed using image softwares that mea-
sure the staining intensity as units of pixels/microscopic ﬁeld examined at 400 magniﬁcation.
Results: OPG was detected as a brown DAB chromogen staining of tissue components express-
ing a positive OPG monoclonal antibody immune reactivity.
Statistical analysis of the results revealed that high OPG level concentrations were found in the
otic capsule followed by the temporal bone and ﬁnally the tibia.
Conclusion: The ﬁndings highlight the role of OPG in inhibition of otic capsule remodeling.
ª 2014 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
Unlike all other bones in the human skeleton, the otic capsule
undergoes very little remodeling after development, possibly
due to local factors produced by the inner ear.1–3
Different types of bone cells normally integrate to achieve a
balanced state of bone metabolism adapting the otic capsule
for the auditory and equilibrium functions occurring withined.
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tion; whereas osteoclasts lead the process of bone remodeling
through its bone resorption activity.4
By the beginning of the last decade, osteoprotegerin (OPG)
was found to act as a key regulator of bone metabolism. OPG
is a naturally occurring protein with potent osteoclastogenesis
inhibitory activity, which plays a key role in the physiological
regulation of osteoclastic bone resorption. OPG is produced
by osteoblasts and marrow stromal cells.5 OPG inhibits differ-
entiation, survival, and fusion of orthoclastic precursor cells
and suppresses activation and promotes apoptosis of osteo-
clasts. Thus, under expression of OPG would show severe oste-
oporosis, whereas over expression of OPG would result in
osteopetrosis.6
The interest for this research is driven by the concern of
otologists to explain the pathogenesis of otosclerosis as one
of the most challenging diseases of the otic capsule.
Otosclerosis is a localized disease of bone remodeling
within the otic capsule of the temporal bone. Unlike other sim-
ilar bone diseases, it does not occur outside of the temporal
bone. These lesions seem to begin by bypassing normal inhibi-
tion of otic capsule remodeling; consequently resorption of sta-
ble otic capsule bone occurs, followed by a reparative phase
with bone deposition.7
Otosclerosis is among the most common causes of acquired
hearing loss. It is considered as a multifactorial disease, caused
by both genetic and environmental factors. Despite the exten-
sive research, the process of development of otosclerosis
remains unclear.8
The present study aimed at characterizing osteoprotegerin
(OPG) as one of the molecules responsible for the unique pat-
tern of bone remodeling in the otic capsule.
Immunohistochemical demonstration of OPG within the
otic capsule of adult normal mice might throw light on the cor-
relation between the density and distribution of OPG and the
development of otosclerotic foci.
In order to conﬁrm this hypothesis, the expression of OPG
in the otic capsule of mice has been compared to its expression
in other skeletal bones known for undergoing a relatively high
rate of turnover and remodeling, namely the surrounding tem-
poral bone and the tibia.
2. Material
2.1. Experimental animals
The present experimental study was conducted in 2011 on 20
normal adult male albino mice with an average weight of
50–60 g. Animal housing at the Physiology department (Alex-
andria Faculty of Medicine) followed the rules of research eth-
ics for experimental animals approved by the Faculty of
Medicine, University of Alexandria.
2.2. Immunohistochemical kit for osteoprotegerin
Osteoprotegerin is a biotinylated monoclonal anti-mouse anti-
body (OPG/TNFRSF11B). The kit is a product by Quantikine
and was purchased via the Egyptian agency for R&D Systems.
It was provided in a 50 lg vial containing 50 lg of bovine
serum albumin per 1 lg antibody lyophilized in a 0.2 lm
ﬁltered solution of phosphate buffered saline.3. Methods
3.1. Harvesting of the specimens
The following specimens were collected from normal adult
male albino mice by microdissection: (1) temporal bone (2) otic
capsule bone surrounding the cochlea, and (3) tibia.
3.2. Preparation and processing
The bone samples (temporal bone, otic capsule and tibia) were
decalciﬁed in 3% trichloroacetic acid solutions at room tem-
perature for 14–21 days. When adequately softened, the sam-
ples were further processed into parafﬁn blocks 5–6 l thick
sections were mounted on ordinary and on positively charged
glass sections for preparation of hematoxylin and eosin sec-
tions and OPG immunolabeled sections respectively.
3.3. Histological technique
Histological technique included light microscopic examination
of parafﬁn sections using routine hematoxylin and eosin
(H&E) stain.
3.4. Immunohistochemical technique
Sections were stained with the universal polyclonal kit
(Thermo scientiﬁc). Antigen retrieval was performed (boiling
slides in 2% citrate buffer for 30 min). Blocking of endogenous
peroxidase activity was performed by incubation with 0.6%
H2O2. Nonspeciﬁc protein staining was blocked by incubation
with the blocking agent provided. Subsequently, sections were
incubated with the primary antibody (at a concentration of 5
and 10 mg/ml (i.e. 1:5 and 1:10 dilution) overnight at 40 C.
On day 2: The secondary antibody was applied for 30 min at
room temperature followed by the linking agent for another
30 min. Diaminobenzidine (DAB) was used as the chromogen.
Each two steps were separated by 2· wash in Tri-HCl buffer
(Lab Vision Co., Fremont, CA, USA). Positive staining was
graded and analyzed using image software that measures the
staining intensity as units of pixels/microscopic ﬁeld examined
at 400 magniﬁcation.9
3.5. Method for image analysis
The concept for applying image analysis software to the OPG
immunolabeled sections of the otic capsule, the associated part
of the petrous temporal bone and the tibia was to quantita-
tively assess and compare the expression of the OPG within
the tissue components of these bones. The sites expressing a
positive immune reaction with the OPG monoclonal antibody
are identiﬁed as brown deposits of the DAB chromogen. The
stronger the immune reaction, the darker the DAB chromogen
intensity. The calculation of the DAB chromogen density was
done by applying digital image analysis. Digital images of
stained sections from the 20 experimented animals were
examined with a computer-assisted light microscope (Olympus
microscope – equipped with Spot 16-bit digital camera
(1280 · 1024 pixel)). Images were viewed and recorded using
computer program MAtLAB software version 5.5 (Image J,
Figure 2 High power view of a section across the mouse right
otic capsule passing through the scala media (SM), the spiral
ligament (SLg), and the scala tympani (ST). The lateral wall of the
otic capsule is formed of compact bone revealing many OPG
positive osteocytes (›) compared to the negative immunostaining
of the stria vascularis (st v) and the endolymph (\) ﬁlling the scala
media.
Figure 1 Light photomicrograph for a cross section proximal to
the apex of the otic capsule and the adjacent petrous part of
temporal bone (T). The boney specules of the otic capsule
demonstrate evident strong positive OPG immune reaction (›)
compared to the faint non speciﬁc reaction depicted in the petrous
temporal bone (*).
Role of osteoprotegerin OPG 49the mathworks, Inc., USA). The maximum, minimum and
integrity of intensity color was based on Gray-level acquisi-
tion, analysis of the data was carried out by reading 10 ﬁxed
areas in one image. The records were taken for 5 images.
3.6. Interpretation of image analysis results
The mean values of each reaction were based on the mean of
the pixel number for each examined microscopic area. Inter-
pretation of the results for pixel analysis of OPG immuno-
staining was built upon the software program for image
analysis which expressed OPG staining density by a value that
was inversely proportional to the measured pixel number.
Accordingly, the larger the pixel number the weaker the
OPG immune expression.10
3.7. Statistical analysis
Data were fed to the computer using IBM SPSS software pack-
age version 20.0. Quantitative data were described using mean,
standard deviation, median, minimum and maximum. Compar-
ison between different groups was analyzed using the F-test
(ANOVA) and the PostHoc test (LSD) for pairwise comparison.
Signiﬁcance test results are quoted as two-tailed probabilities.
Signiﬁcance of the obtained results was judged at the 5% level.
4. Results
4.1. Histological results
The H&E stained histological sections of the petrous part of
the temporal bone demonstrated the normal microscopic anat-
omy of hemisections passing across the mice otic capsule. The
H&E section of the right tibia demonstrated the normal archi-
tecture of the epiphysis, metaphysis and diaphysis.
4.2. Immunohistochemical results
OPG was detected as a brown DAB chromogen staining of tis-
sue components expressing a positive OPG monoclonal anti-
body immune reactivity. The reaction appeared as brown
deposits in cells but was rather a homogenous brownish tinge
in ﬂuids and tissue ground substance.
During the light microscopic examination of immunohisto-
logical sections of the dissected mice sections, the positive
OPG immune reaction could be localized in cells as the osteo-
cytes and osteoblasts of bony tissue of the otic capsule, the
adjacent petrous part of the temporal bone and the tibia. It
could be detected to a lesser extent in chondrocytes within
the hyaline cartilage forming the epiphyseal plate of the tibia
and in the epithelial cells lining the membranous labyrinths
of the semicircular canals.
The intensity of the OPG immune expression in the boney
labyrinths of the otic capsule was generally detectable at the
level of the basal portion as well as near the apical part
(Fig. 1). On the other hand, several other microanatomical
structures within the otic capsule lacked the tendency for
OPG immune expression for instance, the stria vascularis boul-
dering the lateral wall of the scala media within the cochlea, in
which no OPG immune reactivity was detectable (Fig. 2).In addition, to the variation in the intensity of OPG
immune reaction among the bone trabeculae of the otic cap-
sule, it was observed that similar differences were applicable
for the endolymph and perilymph ﬁlling the scala media and
scala tympani respectively. The endolymph exhibited micro-
scopically non detectable OPG immune staining. On the other
hand, the perilymph in the scala tympani and other cavities
within the otic capsule reacted positively to OPG monoclonal
antibody immune staining. The pattern of the reaction was
rather a homogenous, non speciﬁc brown tinge compared to
the speciﬁc strong positive reaction observed in osteocytes
within the adjacent bone trabeculae (Figs. 2 and 3).
Regarding the temporal bone, it was noted that the OPG
expression was generally less evident compared to the bone
trabeculae of the otic capsule. Sections passing across the pet-
rous part of the temporal bone away from the otic capsule
revealed faint non speciﬁc OPG immune reactivity. However,
a detectable OPG positive immune staining was observed in
sections in the temporal bone passing nearer to the otic cap-
sule. The reaction appeared as a localized weak brownish tinge
in the ground substance between the air cells (Fig. 4).
Figure 4 Light photomicrograph for OPG immunostaining of a
normal rat right petrous part of temporal bone. The boney ground
substance (\) between the mastoid air cells (MC) shows weak
brown deposits. Note that few scattered bone cells (›) show a
speciﬁc OPG positive immune reaction.
Figure 5 Light photomicrograph of normal mouse tibia dem-
onstrating an overall faint OPG immunohistochemical reaction. A
brownish positive immunostaining is depicted in scattered bone
cells (›) within the outer table of the compact bone.
Figure 3 High power view of a cross section of the scala tympani
within the mouse right otic capsule. The cavity of the scala
tympani is ﬁlled with residual perilymph showing faint homoge-
nous brownish tinge (\). Note the speciﬁc positive OPG immu-
nostaining of the osteocytes (›) within the layer of compact bone
forming the wall of the cavity.
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the trabeculae of cancellous bone at the metaphysis of the tibia
demonstrated an overall faint afﬁnity to express OPG immune
reaction. Compared to the intensity of OPG expression in the
otic capsule, the reaction is apparently poor (Fig. 5).
4.3. Statistical results for image analysis of the intensity for
(OPG) immunostaining
Interpretation of the results for pixel analysis of the OPG
immunostaining was built upon the software program for
image analysis which expressed the OPG staining density by
a value that was inversely proportional to the measured pixel
number. Accordingly, the larger the pixel number the weaker
the OPG immune expression. The description for strong, mod-
erate and weak OPG immune expression was founded upon
the quantitative grading of the mean pixel value into a scale
for values below 100, a scale ranging between 100 and 140
and a scale above 140 respectively (Table 1).
For the otic capsule near its basal part, OPG immunoex-
pression was the strongest in 10% of the experimented mice(mean pixel value 89.32 and 96.71). It was moderate (mean
pixel value ranging between 107 and 138) in 80% of the mice.
A weak OPG expression was depicted in 10% of the mice
(mean pixel values 142.78 and 172.20).
The apical part of the otic capsule revealed statistical results
for the OPG mean pixel values approximating those of the
basal part of the otic capsule. A strong OPG immunostaining
was expressed in 15% of mice (mean pixel values 95.82.93,
89.32, 95.82), while 20% showed a weak OPG expression
(mean pixel values 145.13, 145.13, 150.09, 150.59). More than
half of the experimented mice sample (65%) demonstrated a
moderately positive OSP labeling (mean pixel value ranging
between 106 and 131).
On analyzing the mean pixel values reﬂecting the OPG
immune reaction in the temporal bone, it was obvious that all
mice failed to express a strong OPG labeling (0% for the mean
pixel value below 100). Only 15% of the mice demonstrated a
moderate OPG immune reaction (mean pixel values 123.99,
123.99, 140.50). The remaining 85% of the mice sample
expressed a weak OPG immune reactivity (mean pixel values
ranging between 142 and 170). (Table 1)
Regarding the OPG immune expression in the perilymph
within the otic capsule, a strong reaction could be depicted
in 15% of the mice (mean pixel values 93.33, 99.16, 99.16).
A moderate OPG reaction could be demonstrated in 35% of
the experimented rat sample (mean pixel values ranging
between 114 and 168); whereas 50% of the animals expressed
a weak reaction (mean pixel values ranging between 143.52
and 160.48).
Compared to the otic capsule, perilymph and the surround-
ing temporal bone, all of the experimented mice failed to reveal
neither strong nor moderate OPG immune expression for the
tibia (0% for mean pixel values below 100 and 0% for values
between 100 and 140). 100% of the experimented rats gave
weak positive OPG immune labeling (mean pixel values rang-
ing between 141 and 186).
The statistical comparison between the mean pixel values
for OPG immune reactivity in the different investigated
parameters indicated that the highest values were demon-
strated in the tibia, followed by the temporal bone, the peri-
lymph, and in the base of the otic capsule and was the
lowest in the apical part of the otic capsule. By interpreting
these values in correlation to the corresponding strength of
the OPG expression, this indicated that the greatest strength
Table 2 Mean, standard deviation and median values of number of pixels measuring the density of immunostaining for (N.B: the
OPG staining density was expressed by a value that was inversely proportional to the measured pixel number. Accordingly, the larger
the pixel number the weaker the OPG immune expression).
OSP-base otic capsule OSP-apex otic capsule OSP-temporal bone OSP-perilymph OSP-tibia
Min.–Max. 96.71–176.30 89.32–150.59 123.99–170.90 93.33–168.61 138.46–189.09
Mean ± SD 126.11 ± 17.80 123.33 ± 17.48 148.59 ± 12.77 137.70 ± 22.74 162.52 ± 13.79
Median 117.72 121.85 148.21 141.06 158.69
p <0.001*
p1 0.611 <0.001
* 0.037* <0.001*
p2 <0.001
* 0.010* <0.001*
p3 0.049
* 0.012*
p4 <0.001
*
p: p value for F test (ANOVA).
p1: p value for Post Hoc test (LSD) for comparing between OPG-base otic capsule and each other place.
p2: p value for Post Hoc test (LSD) for comparing between OPG-apex otic capsule with OSP-temporal bone, OPG-perilymph and OSP-tibia.
p3: p value for Post Hoc test (LSD) for comparing between OPG-temporal bone with OSP-perilymph and OPG-tibia.
p4: p value for Post Hoc test (LSD) for comparing between OPG-perilymph and OPG-tibia.
* Statistically signiﬁcant at p 6 0.05.
Table 1 Quantitative grading of the expressed OPG–Immune.
Percentage of mice
across investigated
parameters
Strong OPG Immune–
expression (mean pixel
value below 100) (%)
Moderate OPG Immune–
expression (mean pixel value
ranging between 100 and 140) (%)
Weak OPG Immune–
expression (mean pixel
value above 140) (%)
Basal part of the
otic capsule
10 80 10
Apical part of the
otic capsule
15 65 20
Temporal bone 0 15 85
Perilymph 15 35 50
Tibia 0 0 100
Role of osteoprotegerin OPG 51could be demonstrated in the base and apex of the otic capsule,
followed by perilymph. It was the least in the temporal bone
and in the tibia (Table 2).
5. Discussion
The pathogenesis of otosclerosis has been a mystery for centu-
ries. Otosclerosis is characterized by abnormal focal bone
remodeling in the bony otic capsule or in rare cases, the ear
ossicles.
Because of recent advances in bone research, it is now
known that RANK, RANKL and OPG are the primary regu-
lators of bone metabolism and that the balance between these
three molecular factors is fundamental in determining the
kinetics of bone turnover at the local level.11
OPG is a powerful inhibitor of bone remodeling. OPG
knockout mice show severe osteoporosis,12 whereas overex-
pression of OPG in transgenic mice causes osteopetrosis.13
The otic capsule, which is the hardest bone in the body, is
unique in its morphology and development. After the onset
of ossiﬁcation at gestational week 16 in humans, the otic cap-
sule forms a unique functional unit in which growth, modeling,
and remodeling in bone are virtually absent.14
This lack of remodeling of bone is the basis for non healing
of fractures of the temporal bone. However, remodeling of
bone within the otic capsule does occur in certain pathologic
disorders such as otosclerosis and Paget’s disease.The biologic mechanism that controls bone metabolism in
the otic capsule and that may be responsible for its low rate
of bone turnover within the otic capsule remains largely
unknown at the present time.
The present study targeted the localization of OPG in the
otic capsule surrounding the cochlea, the temporal bone and
the tibia of normal adult mice. The target for the research done
aimed at exploring the answer to the frequently addressed
question about ‘‘why otosclerosis is unique for the otic
capsule?’’
One of the challenges during processing of the dissected
cochlea and tibia was to reach out for the optimum ﬁxation
and decalciﬁcation protocol that would realize three main
purposes:
1. Bone softening thus permitting adequate sectioning and
staining of bone.
2. Preservation of bone architecture and bone cell morphol-
ogy for microscopic examination.
3. Preservation of tissue antigenicity to serve the purpose of
immunohistochemical identiﬁcation of OPG in bone cells.
Practically, immunohistochemical investigation of parafﬁn-
embedded bone tissue is often hampered by ﬁxation and decal-
ciﬁcation procedures. Routine bone decalcifying agents such as
EDTA and nitric acid not only destroy tissue antigenicity by
denaturing of cell speciﬁc antigens but also entail the
52 Y. Shewel et al.application of time consuming procedures.15 Therefore, we
reverted to 3% trichloroacetic acid as a gentle, less drastic che-
lating agent that achieves optimum bone softening within
3 weeks without denaturation of tissue protein and without
inducing architectural distortion.16
The software program applied to analyze the pixel values
indicating the immune-staining intensities, provided a rough
quantitative estimate for the density of OPG in the anatomical
compartments of the inner ear based upon microscopic immu-
nohistochemical data.
Different concentrations of OPG in ﬁve different places in
experimental animals namely the base of otic capsule, apex
of otic capsule, the temporal bone, the perilymph of the inner
ear and the tibia were measured using immunohistochemistry
and image analysis as methods.
Results found that high OPG level concentrations were
found in the base and apex of the otic capsule followed by
the perilymph then temporal bone and ﬁnally the tibia, which
mean that the higher concentration was in the otic capsule and
the lowest was found in the tibia, and differences in concentra-
tions were statistically different between all areas.
And this explains the much lower rates of bone remodeling
in the otic capsule secondary to the high level of OPG concen-
tration there and the high rate of bone turnover in the tibia
secondary to the low level concentration of OPG in the tibia.
When applied to the otic capsule, normal OPG levels inhi-
bit remodeling and therefore protect against otosclerosis.
External causes disturbing the OPG homeostasis in the otic
capsule would subsequently enhance otosclerosis.17
Several experimental and clinical studies focused on the
correlation between the rate of turnover in the otic capsule,
OPG expression and the localization of otosclerotic foci.
Zehnder et al. and Andreas found that active remodeling
process in the OPG knockout mice has many similarities to
otosclerosis seen in human temporal bones. And they get to
the conclusion that the histopathological and pathophysiolog-
ical ﬁndings in OPG knockout mice support the hypothesis
that OPG is important in the inhibition of bone remodeling
within the otic capsule and the maintenance of normal audi-
tory function.18
Zehnder et al. compared the relative amount of OPG
mRNA that was present in the cochlear soft tissue, otic capsule
bone, calvilear bone, and cortical bone of the femur and was
compared with the mRNA levels for RANKL in those same
tissues. The results found that OPG and RANKL were
expressed in the femur in roughly a 1:1 ratio. However, the
bone of the otic capsule surrounding the cochlea showed an
increased ratio of OPG and RANKL. This study got a conclu-
sion that the ratio of OPG to RANKL is critical in determin-
ing the kinetics of local bone remodeling.19
Furthermore, Kristiansen suggests that OPG is produced in
high levels in the cochlea, and it diffuses into the surrounding
otic capsule by way of a lacuno-canalicular system.19
The correlation between the histological and the immuno-
histochemical results allowed tracking of the distribution of
OPG expression in the different anatomical compartments of
the otic capsule. OPG could be localized, with variable immu-
noexpression densities, within the bony specules forming the
lateral walls of the base and apex of the cochlear, in the mod-
ulus, in the perilymph ﬁlling the scalae vestibuli and tympani
as well as in the endolymph ﬁlling the scala media.The results coincide with the ﬁndings obtained by Kan-
zaki et al. and Bloch et al. , who studied the location of
OPG in the inner ear and the temporal bone in relation to
otosclerotic foci.20,21 However, in contrast to these studies,
the present work was more concerned about the exact local-
ization of OPG in relation to the components of the inner
ear bony labyrinths, both at the cellular as well as at the
anatomical levels, rather than stating its overall positive
immunoreactivity in the otic capsule.
Since OPG has been proved to be protective against bone
remodeling,19 odontologists used it as an antiresorption drug
that would promote bone regeneration and inhibit resorption,
thereby improving the clinical outcome for distraction osteo-
genesis.22 In addition to its applications in odontology, OPG
has been tried for treatment of bone cancer, myeloid myelomas
and other osteolytic bone disorders to inhibit excessive bone
resorption and reduce bone fractures in these patients.23
6. Conclusion and recommendation
Statistical analysis of the results revealed strong OPG expres-
sion in the apex, base and perilymph inside the cochlea. The
lack of OPG in the temporal bone and in the tibia conﬁrms
the peculiar structural and metabolic status of the otic capsule
thus conﬁrming the possible role of a disturbed OPG signaling
as a potent mechanism precipitating the development of
otosclerosis.
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